Genetic Alteration Cell Panels: Effective Tools for High Throughput Screening Using Corning Epic TechnologySeptember 18, 2014, at 12:00 PM ET
Extensive genomic sequencing efforts in recent years have provided detailed profiles of the somatic gene mutations that occur in a wide range of human cancers. In order to facilitate basic and translational cancer research, ATCC has designed and validated a number of Genetic Alteration Cell Panels targeting the key molecular pathways identified in these studies. To demonstrate suitability of the panels for high throughput screening, the EGFR panel was selected for evaluation using Corning Epic Technology, a label-free platform that uses optical biosensors for high sensitivity biochemical and cell-based assays. In this webinar, we will discuss how the combination of Epic Technology and the EGFR Genetic Alteration Panel offers convenient tools to screen for ligands or biologics that directly target or affect EGFR receptor biology.
Fang Tian, PhD
Director, Biological Content, ATCC
Dr. Fang Tian, Lead Scientist, Director of Biological Content for ATCC, has extensive experience in cell biology and molecular biology. She oversees human, animal cell lines and hybridomas, and product development in the Cell Biology General Collection at ATCC. Dr. Tian was a research fellow in Massachusetts General Hospital, Harvard Medical School. She conducted postdoctoral research at the Hillman Cancer Institute of UPMC.
David H. Randle, PhD
Manager, Applications Development, Corning Life Sciences
Do you have other phenotypic characterization data for the ATCC Genetic Alteration Panels in addition to validated gene mutations?
In addition to validating the gene copy number variations and mutations within cell lines, ATCC also tests the related gene expression by real-time PCR and related protein expression by Western blot. In addition, we have characterized the cell growth kinetics, cell morphology, the related protein expression level, and protein cellular location by immunofluorescence staining. This characterization information and data can be found in the ATCC Genetic Alteration Panel brochure on our website.
Do you have purified genomic DNA for the cell lines represented in the ATCC Genetic Alteration Panels?
ATCC is currently producing genomic DNA for most of the cell lines represented in the 10 Genetic Alteration Panels. We will start to release these products in October 2014. These purified genomic DNA preparations are ideal as control materials for molecular diagnostics, as well as for general research purposes.
Is it possible to test the effects of drugs like the EGFR inhibitors in primary cells?
The optical biosensor technology used in Epic is sensitive enough to detect endogenously mediated responses in all cell types including primary and stem cells. This extends also to suspension cells such as primary blood cells, which can be used to evaluate the effects of chemotherapeutic drugs on leukemic cells obtained directly from patients.
Is the sequence data in the ATCC Genetic Alteration Panels generated in-house, or is it acquired from public databases and research articles?
For each of the ATCC Genetic Alteration Panels, all of the genomic data was obtained inhouse at ATCC. This information is available on our website within the ATCC Genetic Alteration brochure.
What other types of targets has Corning Epic Technology been used for in cell-based assays?
Epic has been used successfully for a wide range of targets in cell-based assays. There are now a number of publications demonstrating successful application of Epic for G proteincoupled receptors (GPCRs), where DMR profiles across many different cell backgrounds are highly characteristic of the downstream signaling pathway. In addition to GPCRs and receptor tyrosine kinases (this study), other targets that have been tested successfully on Epic include, ion channels, toll-like receptors, and the Wnt signaling pathway. Finally, longer term assay formats such as cytotoxicity, viral infection and cellular differentiation assays are all feasible using Epic.